Endothelial dysfunction in patients with controlled and uncontrolled arterial hypertension


Cite item

Full Text

Abstract

Aim. To conduct a comparative analysis of the level of asymmetric dimethylarginine (ADMA) in two groups of patients with a diagnosis of essential arterial hypertension (AH). Group I - patients with uncontrolled hypertension (UCAH) and group II - patients with controlled course of hypertension (CAH). Materials and methods. The study included 109 patients: group I - 73 patients with UCAH, group II - 36 patients with CAH. Groups were comparable. Clinical, laboratory and instrumental examination was performed, including determination of ADMA concentration in blood plasma. Results. The concentration of ADMA in patients with UCAH was significantly higher than in the group with CAH. In patients with UCAH, a pronounced positive correlation was found between the concentration of ADMA and creatinine level (r=0.615, p<0.05), and a significant negative correlation was identified between the levels of ADMA and the filtration function of the kidneys, estimated using GFR (r=-0.444, p<0.05). As the level of ADMA in the blood increased, a statistically significant decrease in GFR was detected (p<0.05). Also in the group of patients with UCAH, a significant positive correlation of the average strength was found between the concentration of ADMA and progression of stenosis of brachiocephalic arteries (BCA; r=0.5, p<0.05). Conclusion. A significant increase in ADMA level was revealed in patients of both groups compared to the physiological norm (p<0.05), and it was significantly higher in patients with UCAH compared to those in group II, which indicates that UCAH enhances the severity of endothelial dysfunction. Establishing a reliable correlation between the level of ADMA in patients with UCAH with indicators of renal function damage, progression of BCA stenosis indicates the potential use of this substance as a marker of target organ damage and prognosis of the course of the disease.

About the authors

V I Podzolkov

Sechenov First Moscow State Medical University (Sechenov University)

д.м.н., проф., зав. каф. факультетской терапии №2 лечебного фак-та ПМГМУ им. И.М. Сеченова, ORCID: 0000-0002-0758-5609 Moscow, Russia

T A Safronova

Sechenov First Moscow State Medical University (Sechenov University)

к.м.н., доцент каф. факультетской терапии №2 лечебного фак-та ПМГМУ им. И.М. Сеченова, ORCID: 0000-0002-8348-4770 Moscow, Russia

D U Natkina

Sechenov First Moscow State Medical University (Sechenov University)

Email: dm05_89@mail.ru
соискатель ученой степени к.м.н. каф. факультетской терапии №2 лечебного фак-та ПМГМУ им. И.М. Сеченова; ORCID: 0000-0003-0105-2120 Moscow, Russia

References

  1. Стрюк Р.И., Брыткова Я.В. Дисфункция эндотелия - ранний маркер дебюта артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2014;13(2):110-5.
  2. Gkaliagkousi E, Gavriilaki E, Triantafyllou A. Clinical significance of endothelial dysfunction in essential hypertension. Pathogenesis of hypertension. 2015;17(85):84-92. doi: 10.1007/s11906-015-0596-3
  3. Подзолков В.И., Брагина А.Е., Дружинина Н.А. Прогностическая значимость маркеров эндотелиальной дисфункции у больных с гипертонической болезнью. Российский кардиологический журнал. 2018;4:7-13. doi: 10.15829/1560-4071-2018-4-7-13
  4. Малиновская А.Я. Дисфункция эндотелия у женщин с артериальной гипертензией и патологическим течением климакса и возможности ее коррекции с использованием комбинированной терапии моэксиприлом и дилтиаземом. Рецепт. 2016;1(105):59-71.
  5. Жлоба А.А., Субботина Т.Ф., Алексеевская Е.С. и др. Метаболический предшественник карнитина триметил-L-лизин и метилированные продукты аргинина у пациентов с заболеваниями сердечно - сосудистой системы. Артериальная гипертензия. 2015;21(6):587-94. doi: 10.18705/1607-419X-2015-21-6-587-594
  6. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Annals of Clinical Biochemistry. 2010;47:17-28. doi: 10.1258/acb.2009.009196
  7. Sibal L, Agarwal S.C, Home P.D, Boger R.H. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Current Cardiology Reviews. 2010;6(2):82-90. doi: 10.2174/157340310791162659
  8. Poreba R, Gac P, Poreba M, et al. Left ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertension. Archives of Medical Science. 2015;11(3):521-9. doi: 10.5 114/aoms.2015.52354
  9. Grassi G, Seravalle G, Trevano F.Q, et al. Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. Clin Am Society of Nephrology. 2015;10(9):1560-7. doi: 10.2215/CJN.01220215
  10. Boger R.H, Cooke J.P, and Vallance P. ADMA: an emerging cardiovascular risk factor. Vascular Medicine. 2005;10(Suppl.1):1-2. doi: 10.1177/ 1358836X0501000101
  11. Tsai C.M, Kuo H.C, Hsu C.N, et al. Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. Translation Research. 2014;164(6):452-9. doi: 10.1016/j.trsl.2014.07.005
  12. Klima L, Kawecka-Jaszcz K, Stolarz-Skrzypek K, et al. Structure and function of large arteries in hypertension in relation to oxidative stress markers. Kardiologia Polska. 2013;71(9):917-23. doi: 10.5603/KP.2013.0226
  13. Gonenc A, Hacycevki A, Tavil Y, et al. Oxidative stress in patients with essential hypertension: a comparison of dippers and non - dippers. Eur J Internal Medicine. 2013;24(2):139-44. doi: 10.1016/j.ejim.2012.08.016
  14. Inan B, Ates I, Ozkayar N, et al. Are increased oxidative stress and asymmetric dimethylarginine levels associated with masked hypertension? Сlinical and Experimental Hypertension. 2016;38(3):294-8. doi: 10.3109/10641963.2015.10 89883
  15. Brinkmann S.J, de Boer M.C, Buijs N, van Leeuwen P.A. Asymmetric dimethylarginine and critical illness. Current Opinion in Clinical Nutrition and Metabolic Care. 2014;17(1):90-7. doi: 10.1097/MCO.0000000000000020

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies